Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Chubb
UBS
Argus Health
Cantor Fitzgerald
Johnson and Johnson
Accenture
Express Scripts
AstraZeneca
Harvard Business School
Deloitte

Generated: August 17, 2017

DrugPatentWatch Database Preview

SKELAXIN Drug Profile

« Back to Dashboard

What is the patent landscape for Skelaxin, and what generic Skelaxin alternatives are available?

Skelaxin is a drug marketed by King Pharms and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has two patent family members in two countries.

The generic ingredient in SKELAXIN is metaxalone. There are nineteen drug master file entries for this compound. Thirty-eight suppliers are listed for this compound. Additional details are available on the metaxalone profile page.

Summary for Tradename: SKELAXIN

Patents:2
Applicants:1
NDAs:1
Suppliers / Packagers: see list19
Bulk Api Vendors: see list64
Patent Applications: see list1,097
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:SKELAXIN at DailyMed

Pharmacology for Tradename: SKELAXIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
King Pharms
SKELAXIN
metaxalone
TABLET;ORAL013217-001Approved Prior to Jan 1, 1982DISCNYesNo► Subscribe► Subscribe► Subscribe
King Pharms
SKELAXIN
metaxalone
TABLET;ORAL013217-003Aug 30, 2002ABRXYesYes► Subscribe► Subscribe ► Subscribe
King Pharms
SKELAXIN
metaxalone
TABLET;ORAL013217-003Aug 30, 2002ABRXYesYes► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: SKELAXIN

Drugname Dosage Strength RLD Submissiondate
metaxaloneTablets800 mgSkelaxin11/4/2004

Non-Orange Book Patents for Tradename: SKELAXIN

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,378,434Metaxalone products, method of manufacture, and method of use► Subscribe
6,407,128 Method for increasing the bioavailability of metaxalone► Subscribe
8,168,664Metaxalone products, method of manufacture, and method of use► Subscribe
6,683,102 Methods of using metaxalone in the treatment of musculoskeletal conditions► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: SKELAXIN

Country Document Number Estimated Expiration
Canada2626027► Subscribe
World Intellectual Property Organization (WIPO)2007094825► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Healthtrust
AstraZeneca
Merck
US Department of Justice
Boehringer Ingelheim
Federal Trade Commission
Chubb
QuintilesIMS
Express Scripts
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot